The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Jiao Yang, Hang Sun, and Qi Liu

Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China

Correspondence should be addressed to Qi Liu; qliu8148@163.com

Received 4 January 2016; Revised 20 February 2016; Accepted 17 March 2016

Academic Editor: Manuela Neuman

Copyright © 2016 Jiao Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ACLF. The aim of the study was to compare the efficacy and safety of entecavir with that of lamivudine for HBV-associated ACLF patients.

Methods. Publications on entecavir versus lamivudine in HBV-associated ACLF patients were comprehensively identified. Odds ratio and mean difference were used to measure the effect.

Results. Ten studies, totaling 1254 patients, were eligible. No significant differences between the two drugs presented in the 1-, 2-, 3-, or 6-month survival rates. However, after 12 months of treatment, patients prescribed entecavir had a statistically higher survival rate \((p=0.008)\) and lower total bilirubin \((p<0.0001)\) and alanine aminotransferase \((p=0.04)\) levels compared to patients prescribed lamivudine. More patients achieved HBV negative levels when taking entecavir as measured at 1-, 3-, and 12-month time points and had a lower rate of HBV recurrence.

Conclusion. While entecavir and lamivudine are both relatively safe and well tolerated, entecavir was more efficacious in terms of survival rate and clinical improvement in long-term treatment. Further prospective randomized controlled trials are needed to validate these results.

1. Introduction

Acute-on-chronic liver failure (ACLF), defined as a condition where acute hepatic insult occurs simultaneously with manifestation of jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease [1]. A major cause of ACLF in Asia is chronic hepatitis B virus (HBV) [2]. HBV-associated ACLF has an extremely poor prognosis [3]. There is no standard treatment for ACLF; rather treatment follows the paradigm of addressing the predisposing event, alleviating the inflammatory response and providing supporting care. Artificial liver support is in many cases used as a stabilizing measure for patients with ACLF. However, it is not reckoned to reduce the mortality of patients suffering from ACLF [4, 5]. Currently, liver transplantation is deemed the only really effective therapy for ACLF, but a shortage of suitable donors and the high cost of transplant surgery hinder its clinical application [6, 7]. Therefore, establishment of more effective noninvasive therapeutic strategies is urgently needed.

The mechanism of HBV-associated ACLF remains vague. Nevertheless, viral factors, host factors, and their interactions have great impact on the prognosis of ACLF [8–11]. Nucleos(t)ide analogues such as lamivudine, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF), which suppress the replication of HBV [12, 13], can improve liver function, reduce cirrhotic complications, and decrease the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. More recent, encouraging studies have concluded that antiviral therapy can increase the overall survival rate and ameliorates liver function in patients with HBV-associated ACLF compared with subjects not treated with nucleos(t)ide analogues [14–16].

Entecavir is superior to lamivudine in the suppression of HBV replication with an extremely low mutation rate in
both HBeAg-positive and HBeAg-negative patients [17, 18]. The theoretical cause of entecavir’s success in the long-term treatment of ACLF may lie in the latter’s severe reactivation of HBV. However, the clinical data on the efficacy and safety of entecavir and lamivudine contain the inconsistencies arising from the paucity of larger sample sizes, contemporary controls, and long-term research. Studies conducted by Wen et al. [19], Yuen [20], and Zhang et al. [21] have suggested entecavir’s relative efficacy compared to lamivudine, while one study by Cui et al. [22] found no significant differentials between patients with HBV-associated ACLF treated with entecavir and lamivudine. Therefore, this meta-analysis was performed to explore whether a more thorough analysis of extant study data could settle the vexed question of which was safer and more effective in treating HBV-associated ACLF patients—entecavir or lamivudine?

2. Materials and Methods

2.1. Methods. The research methods follow the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) [23].

2.2. Selection and Exclusion Criteria. In this meta-analysis, randomized controlled trials and cohort studies were eligible with efficacy comparison of entecavir and lamivudine for patients suffering from hepatitis B-associated ACLF.

According to the criteria of acute-on-chronic liver failure (ACLF) from both the Chinese Medical Association and Asian Pacific Association [24], a set of baseline metrics were established for judging study data on patients with hepatitis B-associated ACLF. Studies were eligible when the subjects met the following criteria:

1. The presence of serumal hepatitis B surface antigen (HBsAg) for at least 6 months.
2. HBV DNA level \(>10^5\) copies/mL.
3. Serum total bilirubin (TBIL) concentration \(>85\mu\text{mol/L}\) and plasma prothrombin activity \(<40\%\text{ or international standard ratio (INR) }\geq 1.5\).
4. No complications or comorbidities such as hepatic encephalopathy or abrupt and obvious increase of ascites or spontaneous bacterial peritonitis.

Studies conforming to any of the following criteria were excluded:

1. Coinfection with hepatitis A, hepatitis C, hepatitis D, hepatitis E, cytomegalovirus, or human immunodeficiency virus (HIV).
2. Other concomitant liver diseases, such as drug hepatitis, alcoholic liver disease, autoimmune hepatitis, or Wilson’s disease.
3. Patients suffering from serious medical disease or tumor.
4. A previous course of any antiviral therapy during the preceding 6 months.

2.3. Data Collection Process. A comprehensive search was completed of the Cochrane Central Register of Controlled Trials, PubMed, Medline, Embase, China National Knowledge Infrastructure (CNKI), and the Chinese BioMedical Literature Database. In addition, reference items of the eligible studies and relevant reviews were checked for qualified studies. The following keywords were searched: “entecavir”, “lamivudine”, “nucleoside analogue”, “nucleotide analogue”, “liver failure”, “hepatic failure”, “acute on chronic liver failure”, and “chronic hepatitis B”. The search strategy used in PubMed is as follows: “(acute-on chronic liver failure [Title/Abstract]) AND (HBV) AND (entecavir OR nucleoside analogues OR nucleotide analogues)”. Two researchers (Jiao Yang and Hang Sun) independently conducted the literature retrieval, study selection, and data extraction. Differences in assessment were resolved by consensus.

2.4. Assessment of Study Quality. For randomized controlled trials (RCTs), the Cochrane risk of bias tool including random sequence generation, allocation concealment, blindness of participants and personnel, blindness outcome assessment, incomplete outcome data, selective reporting, and other sources of bias was used to evaluate the quality of the included studies. Newcastle-Ottawa Scale (NOS) involving the selection of cohorts, comparability of cohorts, and assessment of the outcomes was applied to assess the quality of observational cohort studies. Studies with an overall score \( \geq 7\) were defined as high-quality.

2.5. Efficacy Measures. The primary efficacy endpoint was overall survival rate of different time points. Secondary efficacy endpoints were recurrence rate of HBV, incidence of HBV negative, TBIL, ALT, and PTA changes as measures of hepatic improvement. The safety of entecavir and lamivudine was also assessed in the meta-analysis.

2.6. Data Analysis. The analysis was conducted by the use of RevMan 5.3 (Nordic Cochrane Centre, Cochrane Collaboration). A \( p \) value of less than 0.05 was regarded as statistically significant. Heterogeneity was assessed using the \( \chi^2 \) square test and \( I^2 \) statistic. \( I^2 < 50\% \) or \( p > 0.10 \) was considered to indicate no significant heterogeneity between studies and the fixed-effects model was employed to analyze the data. Otherwise, the random-effects model was used. Publication bias was evaluated by a funnel plot. Odds ratio (OR), mean difference (MD), and 95% confidence interval (CI) were used as effect measurements.

3. Results

3.1. Study Selection. Of the 1687 manuscripts identified, 735 duplicates were removed. 10 studies [19, 21, 22, 25–31] were selected as eligible for the next phase of detailed analysis. 1254 patients (629 using entecavir and 625 for lamivudine) in total met the inclusion criteria for this meta-analysis (Figure 1). Of the included studies, four were randomized controlled trials, two were prospective cohort studies, and four were retrospective cohort studies. All the studies were performed
in China. The dosages of entecavir and lamivudine were unified in the eligible studies. All patients included were given routine comprehensive treatment, including intensive care monitoring, nutritional supplementation, and plasma, electrolyte, and acid-base equilibrium, and prophylaxis and treatment of complications. The baseline characteristics of the eligible studies are shown in Table 1.

3.2. Risk of Bias in Included Studies. The overall quality of the eligible studies in this meta-analysis was suboptimal. There were four RCTs in the meta-analysis. For the RCTs, selection bias, reporting bias, and other biases were not clear, performance bias was high, and attrition bias was low (Figure 3). The quality of cohort studies was shown in Table 2. No obvious publication bias was found (Figure 4).

3.3. Efficacy Comparison

3.3.1. Overall Survival Rates

(1) One-Month Survival Rate. Five studies reported the details of survival rates at one month, with a total of 504 patients (249 patients using entecavir and 255 taking lamivudine). No significant heterogeneity was observed between these studies ($I^2 = 0\%$ and $p = 0.97$) and the fixed effect model was used. Comparable survival rates at this time point between patients given entecavir and those on lamivudine (86.75\% versus 81.96\%; OR: 1.52; 95\% CI: 1.09, 2.15; $p: 0.01$) are shown in Figure 2.

(2) Two-Month Survival Rate. Four studies involving 186 patients using entecavir and 184 using lamivudine reported the data regarding two-month survival rates. Patients using entecavir had no significant difference in two-month survival rate compared to those on lamivudine (72.58\% versus 65.22\%; OR: 1.48; 95\% CI: 0.94, 2.32; $p: 0.09$). The assessment of heterogeneity acquired $p = 0.87$ in Cochran’s $Q$ test and $I^2 = 0\%$, meaning no variability of the included studies (Figure 2).

(3) Three-Month Survival Rate. Six studies provided three-month survival rate data. We included 318 patients taking entecavir and 319 using lamivudine. $I^2 = 0\%$ and $p = 0.87$ indicated no significant heterogeneity in those studies and the fixed effect model was applied. Comparative data on improvements in the three-month survival rate between patients with entecavir and those using lamivudine (67.92\% versus 67.08\%; OR: 1.06; 95\% CI: 0.75, 1.54; $p: 0.75$) are also shown in Figure 2.

(4) Six-Month Survival Rate. Data regarding overall six-month survival rates were presented in three studies with 193 patients in the entecavir group and 214 in that of lamivudine. We found that entecavir was no better than lamivudine in raising the six-month survival rate for patients with chronic hepatitis B-associated acute-on-chronic liver failure (74.09\% versus 73.83\%; OR: 0.98; 95\% CI: 0.61, 1.57; $p: 0.94$). $I^2 = 0\%$ and $p = 0.94$ showed no obvious heterogeneity among those studies (Figure 2).

(5) Twelve-Month Survival Rate. Five studies had information on overall twelve-month survival rates, including 344 patients taking entecavir and 349 taking lamivudine. Patients on entecavir had a higher overall survival rate than those on lamivudine (84.30\% versus 77.08\%; OR: 1.79; 95\% CI: 1.17, 2.75; $p: 0.008$). Due to the limited heterogeneity between the eligible studies ($I^2 = 0\%$ and $p = 0.76$), the fixed effect model was used (Figure 2).

3.3.2. HBV DNA Negative

(1) One-Month HBV DNA Negative. Six studies with 382 patients in the entecavir group and 353 in the lamivudine cohort reported the incidence of one-month HBV DNA negative changes. No significant heterogeneity was found ($I^2 = 0\%$ and $p = 0.74$). Therefore, the fixed effect model was used. Patients given entecavir presented a higher HBV DNA negative rate than subject on lamivudine at one month (65.71\% versus 43.91\%; OR: 2.85; 95\% CI: 2.06, 3.94; $p < 0.00001$) (Table 3).

(2) Two-Month HBV DNA Negative. Data on the HBV DNA negative rate at three months were available in three studies. These studies included 236 patients taking entecavir and 229 taking lamivudine. More patients with entecavir achieved negative levels of HBV DNA than those with lamivudine (86.44\% versus 64.63\%; OR: 3.49; 95\% CI: 2.20, 5.53; $p < 0.00001$). With $I^2 = 0\%$ and $p = 0.83$ the lack of significant heterogeneity led to the application of the fixed effect model was applied (Table 3).

(3) Twelve-Month HBV DNA Negative. Three studies comprising 215 patients on entecavir and 201 on lamivudine reported data on twelve-month HBV DNA negativity. No apparent heterogeneity was found between those studies ($I^2 = 0\%$ and $p = 0.84$). Entecavir largely enhanced rates of
| Study                  | Region | Study design | Number of patients | HBV DNA log10 copies/mL | HBeAg-positive PTA (%) or INR (means ± SD) | TBIL (means ± SD) (%) | ALB (means ± SD) (%) | ALT (means ± SD) (%) | Treatment duration (months) |
|-----------------------|--------|--------------|--------------------|-------------------------|--------------------------------------------|------------------------|---------------------|----------------------|--------------------------|
| Hu et al., 2010 [25]  | China  | cohort       | 90                 | 90                      | 8.2 ± 1                                    | 8.2 ± 1                | NA                  | NA                   | NA                       | 6                        |
| Gao et al., 2015 [26] | China  | cohort       | 46                 | 66                      | NA                                         | NA                     | NA                  | NA                   | NA                       | 24                       |
| Cui et al., 2010 [22] | China  | cohort       | 33                 | 34                      | 5.9 ± 1.5                                  | 5.9 ± 1.5              | 10                  | 13                   | 2.27 ± 0.55              | 2.61 ± 1.03               | 20.10 ± 11.24            | 19.91 ± 8.56              | 33.36 ± 4.43              | 31.64 ± 5.32              | 364 (47–2601)            | 226.5 (22–2314)          | 3                        |
| Chen et al., 2012 [27]| China  | cohort       | 42                 | 30                      | 7.04 ± 1.6                                 | 7.25 ± 0.89            | NA                  | NA                   | 34.88 ± 12.27           | 32.18 ± 11.44             | 326.29 ± 201.35          | 332.65 ± 182.65          | 31.45 ± 5.79             | 29.59 ± 5.63              | 324.19 ± 310.04          | 287.61 ± 261.50          | 3                        |
| Tsai et al., 2013 [28]| China  | cohort       | 93                 | 89                      | NA                                         | NA                     | NA                  | NA                   | 34.6 ± 8.1               | 34.8 ± 9.6               | 256.5 ± 137.4            | 257.6 ± 135.9            | 31.4 ± 4.6               | 32.8 ± 4.5               | 395.4 ± 235.3            | 387.1 ± 245.4            | 3                        |
| Zhang et al., 2014 [21]| China | cohort       | 65                 | 54                      | 7 ± 1.4                                    | 7.2 ± 1.6              | 21                  | 23                   | 24.7 ± 6.0              | 25.1 ± 5.7               | 331.6 ± 74.8             | 330.1 ± 82.4             | 28.7 ± 6.9              | 29.4 ± 5.3               | 352.5 ± 77.2             | 345.2 ± 89.5             | 13                       |
| Wen et al., 2010 [19] | China  | RCT          | 46                 | 47                      | NA                                         | NA                     | NA                  | NA                   | 29.8 ± 8.5               | 30.6 ± 9.1               | 375.2 ± 200.3            | 389.4 ± 198.1            | 31.4 ± 4.6              | 32.7 ± 3.9               | 402.5 ± 292.7            | 395.8 ± 297.4            | 12                       |
| Cai and Shi, 2011 [29]| China  | RCT          | 38                 | 34                      | NA                                         | NA                     | NA                  | NA                   | 34.6 ± 8.1               | 34.8 ± 9.6               | 256.5 ± 137.4            | 257.6 ± 135.9            | 31.4 ± 4.6              | 32.8 ± 4.5               | 395.4 ± 235.3            | 387.1 ± 245.4            | 12                       |
| He, 2013 [30]         | China  | RCT          | 57                 | 57                      | 6.2 ± 2.1                                  | 6.1 ± 1.9              | NA                  | NA                   | 30 ± 8                   | 30 ± 8                   | 339 ± 135                | 342 ± 148                | 31 ± 6                  | 31 ± 6                   | 399 ± 245                | 404 ± 237                | 6                        |
| Yuan, 2015 [31]       | China  | RCT          | 149                | 148                     | NA                                         | NA                     | NA                  | NA                   | 33.89 ± 7.78            | 33.96 ± 7.80             | 260.41 ± 140.11          | 260.38 ± 140.10          | 31.88 ± 6.11            | 31.89 ± 6.10             | 396.31 ± 240.12          | 397.00 ± 240.22          | 12                       |

ETV: entecavir; LAM: lamivudine; NA: not available; PTA: prothrombin activity; INR: international standard ratio; TBIL: total bilirubin; ALB: albumin; ALT: alanine aminotransferase; RCT: randomized controlled studies.
| Study or subgroup | ETV Events | LAM Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------|------------|--------|-----------------------------|-----------------------------|
| Cai and Shi 2011 | 32 38      | 27 34      | 18.3%  | 1.38 [0.41, 4.61]           |                             |
| Chen et al. 2012 | 33 42      | 20 30      | 20.3%  | 1.83 [0.64, 5.28]           |                             |
| Cui et al. 2010  | 26 33      | 23 34      | 19.5%  | 1.78 [0.59, 5.34]           |                             |
| Gao et al. 2015  | 39 46      | 52 66      | 26.4%  | 1.50 [0.55, 4.07]           |                             |
| Hu et al. 2010   | 86 90      | 87 91      | 15.6%  | 0.99 [0.24, 4.08]           |                             |
| **Total (95% CI)** | **249** | **255** | **100.0%** | **1.52 [0.92, 2.52]** | **1.52 [0.92, 2.52]** |

(a)

| Study or subgroup | ETV Events | LAM Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------|------------|--------|-----------------------------|-----------------------------|
| Cai and Shi 2011 | 30 38      | 25 34      | 8.4%   | 1.35 [0.45, 4.02]           |                             |
| Chen et al. 2012 | 29 42      | 18 30      | 9.9%   | 1.49 [0.56, 3.96]           |                             |
| Cui et al. 2010  | 16 33      | 17 34      | 13.1%  | 0.94 [0.36, 2.45]           |                             |
| Gao et al. 2015  | 36 46      | 49 66      | 28.3%  | 1.25 [0.51, 3.05]           |                             |
| Hu et al. 2010   | 60 90      | 63 91      | 31.7%  | 0.89 [0.48, 1.66]           |                             |
| Lai et al. 2013  | 45 69      | 44 64      | 24.1%  | 0.85 [0.41, 1.76]           |                             |
| **Total (95% CI)** | **318** | **319** | **100.0%** | **1.06 [0.75, 1.48]** | **1.06 [0.75, 1.48]** |

(b)

| Study or subgroup | ETV Events | LAM Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------|------------|--------|-----------------------------|-----------------------------|
| Gao et al. 2015  | 33 46      | 44 66      | 29.2%  | 1.27 [0.56, 2.88]           |                             |
| He 2013          | 56 57      | 54 57      | 2.7%   | 3.11 [0.31, 30.84]          |                             |
| Hu et al. 2010   | 54 90      | 60 91      | 68.1%  | 0.78 [0.42, 1.42]           |                             |
| **Total (95% CI)** | **193** | **214** | **100.0%** | **0.98 [0.61, 1.57]** | **0.98 [0.61, 1.57]** |

(c)

| Study or subgroup | ETV Events | LAM Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------|------------|--------|-----------------------------|-----------------------------|
| Cai and Shi 2011 | 29 38      | 24 34      | 19.1%  | 1.34 [0.47, 3.84]           |                             |
| Gao et al. 2015  | 33 46      | 42 66      | 31.0%  | 1.45 [0.64, 3.28]           |                             |
| Wen et al. 2010  | 37 46      | 29 47      | 17.9%  | 2.55 [1.00, 6.51]           |                             |
| Yuan 2015        | 149 149    | 148 148    | Not estimable |                 |                             |
| Zhang et al. 2014| 42 65      | 26 54      | 32.0%  | 1.97 [0.94, 4.11]           |                             |
| **Total (95% CI)** | **344** | **349** | **100.0%** | **1.79 [1.17, 2.75]** | **1.79 [1.17, 2.75]** |

(d)

| Study or subgroup | ETV Events | LAM Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------|------------|--------|-----------------------------|-----------------------------|
| Cai and Shi 2011 | 29 38      | 24 34      | 19.1%  | 1.34 [0.47, 3.84]           |                             |
| Gao et al. 2015  | 33 46      | 42 66      | 31.0%  | 1.45 [0.64, 3.28]           |                             |
| Wen et al. 2010  | 37 46      | 29 47      | 17.9%  | 2.55 [1.00, 6.51]           |                             |
| Yuan 2015        | 149 149    | 148 148    | Not estimable |                 |                             |
| Zhang et al. 2014| 42 65      | 26 54      | 32.0%  | 1.97 [0.94, 4.11]           |                             |
| **Total (95% CI)** | **344** | **349** | **100.0%** | **1.79 [1.17, 2.75]** | **1.79 [1.17, 2.75]** |

(e)

Figure 2: (a) Comparison of 1-month survival rates between patients taking entecavir and those taking lamivudine. (b) Comparison of 2-month survival rate between patients taking entecavir and those taking lamivudine. (c) Comparison of 3-month survival rates between patients taking entecavir and those taking lamivudine. (d) Comparison of 6-month survival rates between patients taking entecavir and those taking lamivudine. (e) Comparison of 12-month survival rates between patients taking entecavir and those taking lamivudine.
Table 2: Quality assessment of the eligible observational cohort studies.

| Studies included          | Selection | Comparability | Outcome | Scores |
|---------------------------|-----------|---------------|---------|--------|
| Huetal., 2010 [25]        | √         | √             | √       |        |
| Gao et al., 2015 [26]     | √         | √             | √       |        |
| Cui et al., 2010 [22]     | √         | √             | √       |        |
| Chen et al., 2012 [27]    | √         | √             | √       |        |
| Lai et al., 2013 [28]     | √         | √             | √       |        |
| Zhang et al., 2014 [21]   | √         | √             | √       |        |

For cohort studies, 1 indicates exposed cohort truly representative; 2 nonexposed cohort drawn from the same community; 3 ascertainment of exposure; 4 outcome of interest not present at start; 5 cohorts comparable based on the most important factors; 6 cohorts comparable on other factors; 7 quality of outcome assessment; 8 follow-up long enough for outcomes to occur; and 9 adequacy of follow-up of cohorts.

![Risk of bias graph](image)

(a) Risk of bias graph

![Risk of bias summary](image)

(b) Risk of bias summary

Figure 3: (a) Risk of bias graph: review of authors’ judgments about each risk of bias item presented as percentages across all included RCTs. (b) Risk of bias graph: review of authors’ judgments about each risk of bias item for each included study.
Table 3: Efficacy comparison of entecavir and lamivudine for dichotomous outcomes.

| Outcome of interest | Number of studies | Entecavir | | Lamivudine | | Effect estimate | | Heterogeneity | |
|---------------------|-------------------|-----------|---|-----------|---|-----------------|---|-----------------|
|                     |                   | Sample size | Events | Sample size | Events | OR (95% CI) | p value | I² (%) | p value |
| Overall survival    |                   |            |       |            |       |               |         |        |         |
| 1 month             | 5                 | 249        | 216   | 255        | 209   | 1.52 (0.92, 2.52) | 0.1 | 0 | 0.97 |
| 2 months            | 4                 | 186        | 135   | 184        | 120   | 1.48 (0.94, 2.32) | 0.09 | 0 | 0.87 |
| 3 months            | 6                 | 318        | 216   | 319        | 214   | 1.06 (0.75, 1.48) | 0.75 | 0 | 0.87 |
| 6 months            | 3                 | 193        | 143   | 214        | 158   | 0.98 (0.61, 1.57) | 0.94 | 0 | 0.38 |
| 12 months           | 5                 | 344        | 290   | 349        | 269   | 1.79 (1.17, 2.75) | 0.008 | 0 | 0.76 |
| HBV DNA negative    |                   |            |       |            |       |               |         |        |         |
| 1 month             | 6                 | 382        | 251   | 353        | 155   | 2.85 (2.06, 3.94) | <0.00001 | 0 | 0.74 |
| 3 months            | 3                 | 236        | 204   | 229        | 148   | 3.49 (2.20, 5.53) | <0.00001 | 0 | 0.83 |
| 12 months           | 3                 | 215        | 208   | 201        | 156   | 8.61 (3.79, 19.59) | <0.00001 | 0 | 0.84 |
| Recurrence of HBV   | 4                 | 154        | 0     | 165        | 18    | 0.07 (0.01, 0.40) | 0.003 | 0 | 0.93 |

OR: odds ratio; CI: confidence interval.

Figure 4: (a) Funnel plot of 1-month survival rate. (b) Funnel plot of 3-month survival rate. (c) Funnel plot of 12-month survival rate. (d) Funnel plot of the incidence of 1-month HBV negative status.
HBV DNA negative compared with lamivudine in hepatitis B-associated acute-on-chronic liver failure. This outcome seemed relatively stable irrespective of the duration of the antiviral therapy (Table 3).

### 3.3.3. Recurrence of HBV

Four studies comprising 154 patients taking entecavir and 165 patients using lamivudine reported the information of recurrence of HBV. No patients in entecavir group experienced a recurrence of HBV compared to 18 in the lamivudine cohort. Entecavir treatment significantly reduced the recurrence rate of HBV in patients with HBV-associated ACLF compared to patients taking lamivudine (0% versus 10.91%; OR: 0.07; 95% CI: 0.01, 0.40; p < 0.0001). Therefore, the fixed effect model was applied. Our results showed a comparable reduction in the entecavir group compared to those taking lamivudine (MD: −6.08, −0.07, p = 0.29) (Table 4).

### 3.3.6. PTA Changes

Four studies with a total of 283 subjects in their entecavir groups and 274 in lamivudine groups, reported the changes of PTA at one month. The sensitivity analysis was performed to confirm the stability of the primary analysis by excluding studies one by one. We found out that the overall heterogeneity was low (I² = 21% and p = 0.29) showing low heterogeneity and fixed effect model was applied. Patients taking entecavir showed higher rates of improvement of PTA than those with lamivudine after treatment for one month (MD: 2.12, 95% CI: 0.42, 3.82, p = 0.01) (Table 4).

Three studies reported the changes of PTA at three months and twelve months. No significant heterogeneity was measured between studies about PTA at three months and twelve months (I² = 0%, p = 0.76 for the former; I² = 0% and p = 0.99 for the latter). Patients with entecavir showed no significant improvement of PTA compared to those with lamivudine for three months and twelve months (MD: 1.91, 95% CI: −1.33, 5.15, p = 0.25; MD: 3.6, 95% CI: −1.07, 8.26, resp.) (Table 4).

### 3.4. Safety

No studies reported serious adverse events attributable to entecavir or lamivudine, nor did they report any drug-related viral mutation. All the patients tolerated the treatment without modification of dose or early discontinuation.

### 3.5. Sensitivity Analysis

The sensitivity analysis was performed to confirm the stability of the primary analysis by excluding studies one by one. We found out that the overall survival rate, HBV DNA negative, and recurrence of HBV did not change significantly with the exclusion of any single study.

### 4. Discussion

ACLF is a serious condition with a high mortality. Nearly two-thirds of patients may die without liver transplantation...
The mechanisms of HBV-associated ACLF are extremely intricate and complex and, as a result, not yet established. Nevertheless, one of the important mechanisms is the overactivity of immune response including the excess activity of HBcAg/HBeAg-specific T cells and involvement of B lymphocytes activity and peripheral glucocorticoid receptor expression [34].

Up to now, there has been no effective treatment for patients with HBV-associated ACLF. Therefore, it is critical to improve medical therapy for patients with HBV-associated ACLF as a key aim in extending periods of survival. Zhao et al.'s study suggested that HBV replication and mutation were the primary factor which may lead to chronic and acute liver failure [35]. As such, antiviral therapy by inhibition of HBV replication may be helpful in postponing the progression of liver failure and reducing the mortality of patients with HBV-associated ACLF. Though the efficacy of lamivudine and entecavir is controversial in the treatment of HBV-associated ACLF, recent studies had proven that both lamivudine and entecavir can decrease the mortality, improve the biochemical response, and effectively suppress the replication of HBV in patients with HBV-associated ACLF [14, 15]. Further studies have shown that a profound and rapid reduction of HBV DNA is effected by entecavir treatment but not by lamivudine. Accordingly, it appears that entecavir may be more efficacious than lamivudine in the treatment of HBV-associated ACLF.

In this meta-analysis, we made an efficacy comparison of entecavir and lamivudine in patients suffering from HBV-associated ACLF across ten eligible studies. The efficacy comparison outcomes were the overall survival rate, HBV DNA negativity, the recurrence of HBV, and the biochemical parameters (changes of TBIL, ALT, and PTA). The outcomes at different time points were different.

Though no statistically significant data was found, there was a discoverable tendency toward superiority of the entecavir therapy over the lamivudine in terms of survival rates at one, two, three, and six months. These outcomes are in accordance with Chen et al.'s study [27]. In the latter study, patients with entecavir and lamivudine had a similar accumulative survival rate during the first three months of treatment (66.7% versus 60%). However, patients with entecavir had significantly higher survival rate than those with lamivudine after treatment of twelve months. Those results suggest that entecavir outperforms lamivudine not in short-term survival but in that of the long term. Here, the short term was defined as not more than six months. The changes of TBIL and ALT were in line with the data on overall survival rates. Our results suggested a comparable efficacy in lowering the level of TBIL and ALT in subjects prescribed entecavir and those taking lamivudine, at least, in the short term. However, patients on entecavir acquired significantly lower TBIL and ALT levels after treatment for twelve months. PTA level at one month was significantly lower in the entecavir group than that in lamivudine subjects. Nevertheless, we found no significant difference in changes of PTA for patients with long-run use of entecavir and lamivudine. In general, both entecavir and lamivudine have the capacity to alleviate hepatic injury and improve liver function. But in the long run, entecavir may be superior to lamivudine in biochemical response. More patients on entecavir obtained HBV negative scores at one-, three-, and twelve-month time points than those on lamivudine, while, in addition, entecavir subjects had either very low or unmeasurable levels of HBV as compared to those on lamivudine. These results are attributed to entecavir's potency in suppressing HBV replication as well as the low level of mutations engendered by entecavir. These results are consistent with previous studies. As a whole, long-term use of entecavir could raise survival rates and improved patients' biochemical response, over and above its primary function to reduce virological replication rapidly for patients with HBV-associated ACLF.

However, there has been one perennial concern regarding entecavir administration in cases of chronic HBV-associated liver failure, which is acute lactic acidosis. A recent study reported that serious lactic acidosis occurred more often in patients with high MELD scores and multigran failure [36]. Patients in the eligible studies were mostly those with early- to mild-stage HBV-associated ACLF. Therefore, no serious adverse effects occurred as a result of the on occasion severe lactic acidosis in the meta-analysis.

The degree of hepatic necrosis, rather than the viral load, is the central determinant of short-term mortality in cases of HBV-associated ACLF [37, 38]. Therefore, the primary goal of antiviral therapy is as viral prevention in case of further liver transplantation and HBV reactivation. Moreover, cost may be a factor as lamivudine is cheaper than entecavir. As such, lamivudine may be a viable alternative in the first stages of treatment and restricted to short-term use. Routine switching to entecavir after liver function has improved or the adoption of the roadmap concept is reasonable treatment strategies for patients with HBV-associated ACLF [39].

Our study had a few limitations. Firstly, not all the eligible studies offered full datasets which satisfied requisite parameters. These gaps in data resulted in small sample sizes presenting different outcomes at different time points. The limited sample size itself might be deemed to weaken the validity of the conclusions. Secondly, there were only four randomized controlled trials and the quality of those RCTs was suboptimal. Therefore, higher-quality RCTs are a vital next step in validating our findings. Thirdly, all the eligible studies were conducted in China, rendering our conclusions potentially unsuitable for other populations. Fourthly, the conditions of eligible patients mainly are mild to moderate. Therefore, maybe our results are not conforming to patients with severe symptoms. Lastly, articles published in full text and published in English or Chinese were retrieved. There was a high probability of overlooking the eligible studies published in other languages or only in abstract.

5. Conclusion

In conclusion, short-term treatment with both entecavir and lamivudine are effective in increasing the survival rate and counteracting hepatic injury for patients with early-to-mild stage HBV-associated ACLF. But for long-term therapy,
entecavir has more advantages than lamivudine, whether measured by survival rates or clinical improvement. In addition, entecavir and lamivudine were equally well tolerated during the treatment.

**Competing Interests**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Qi Liu was responsible for study conception and design. Jiao Yang and Hang Sun contributed with data acquisition and analysis. Jiao Yang wrote the paper. Qi Liu and Hang Sun critically revised the paper. All the authors read and approved the final paper.

**Acknowledgments**

This work was supported by Institute of Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University.

**References**

[1] S. K. Sarin, A. Kumar, J. A. Almeida et al., “Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL),” in Hepatology International, vol. 3, article 269, 2009.

[2] L. J. Sun, J. W. Yu, Y. H. Zhao, P. Kang, and S. C. Li, “Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure,” Journal of Gastroenterology and Hepatology, vol. 25, no. 3, pp. 583–590, 2010.

[3] C. Vickers, J. Neuberger, J. Buckel, P. McMaster, and E. Elias, “Transplantation of the liver in adults and children with fulminant hepatic failure,” Journal of Hepatology, vol. 7, no. 2, pp. 143–150, 1988.

[4] X. Xu, X. Liu, Q. Ling et al., “Artificial Liver Support System Combined with Liver Transplantation in the Treatment of Patients with Acute-On-Chronic Liver Failure,” PLoS ONE, vol. 8, no. 3, p. e58738, 2013.

[5] V. Stadlbauer, N. A. Davies, S. Sen, and R. Jalan, “Artificial liver support systems in the management of complications of cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 96–109, 2008.

[6] R. Bahirwani, O. Shaked, M. Bewtra, K. Forde, and K. R. Reddy, “Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes,” Transplantation, vol. 92, no. 8, pp. 952–957, 2011.

[7] A. C. Chan, S. T. Fan, C. M. Lo et al., “Liver transplantation for acute-on-chronic liver failure,” Hepatology International, vol. 3, no. 4, pp. 571–581, 2009.

[8] X. Ren, Z. Xu, Y. Liu et al., “Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis,” Journal of Viral Hepatitis, vol. 17, no. 12, pp. 887–895, 2010.

[9] J.-Y. Zhang, Z. Zhang, F. Lin et al., “Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B,” Hepatology, vol. 51, no. 1, pp. 81–91, 2010.

[10] Q. L. Song, X. X. He, H. Yang et al., “Association of a TANK gene polymorphism with outcomes of hepatitis B virus infection in a Chinese Han population,” Viral Immunology, vol. 25, no. 1, pp. 73–78, 2012.

[11] Y. Rong, H. Song, S. You et al., “Association of toll-like receptor 3 polymorphisms with chronic hepatitis b and hepatitis b-related acute-on-chronic liver failure,” Inflammation, vol. 36, no. 2, pp. 413–418, 2013.

[12] C. Haché and J.-P. Villeneuve, “Lamivudine treatment in patients with chronic hepatitis B and cirrhosis,” Expert Opinion on Pharmacotherapy, vol. 7, no. 13, pp. 1835–1843, 2006.

[13] Y. F. Liaw, J. J. Sung, W. C. Chow et al., “Cirrhosis Asian Lamivudine Multicentre Study Group: lamivudine for patients with chronic hepatitis B and advanced liver disease,” The New England Journal of Medicine, vol. 351, pp. 1521–1531, 2004.

[14] X. Zhang, L. Liu, M. Zhang et al., “The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis,” Annals of Hepatology, vol. 14, no. 2, pp. 150–160, 2015.

[15] S. Yu, H. Jianqin, W. Wei et al., “The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis,” Annals of Hepatology, vol. 12, no. 3, pp. 364–372, 2013.

[16] F. Xie, L. Yan, J. Lu et al., “Effects of nucleotide analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis,” PLoS ONE, vol. 8, no. 1, Article ID e54773, 2013.

[17] T.-T. Chang, R. G. Gish, R. de Man et al., “A comparison of entecavir and lamivudine for HBBeAg-positive chronic hepatitis B,” New England Journal of Medicine, vol. 354, no. 10, pp. 1001–1010, 2006.

[18] C.-L. Lai, D. Shouval, A. S. Lok et al., “Entecavir versus lamivudine for patients with HBBeAg-negative chronic hepatitis B,” New England Journal of Medicine, vol. 354, no. 10, pp. 1010–1020, 2006.

[19] B. Wen, J. Tuan, M. D. Hu, J. H. Zhang, M. Wu, and S. M. Yao, “A comparison of entecavir and lamivudine for subacute-on-chronic liver failure infected with HBV,” Journal of Tropical Medicine, vol. 10, pp. 183–185, 2010 (Chinese).

[20] M. F. Yuen, “Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure,” Hepatology International, vol. 9, no. 3, pp. 373–377, 2015.

[21] Y. Zhang, X.-Y. Hu, S. Zhong et al., “Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure,” World Journal of Gastroenterology, vol. 20, no. 16, pp. 4745–4752, 2014.

[22] Y. L. Cui, F. Yan, Y. B. Wang et al., “Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure,” Digestive Diseases and Sciences, vol. 55, no. 8, pp. 2373–2380, 2010.

[23] D. Moher, L. Shamseer, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” Systematic Reviews, vol. 4, no. 1, 2015.

[24] S. K. Sarin, C. K. Kedarisetty, Z. Abbas et al., “Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014,” Hepatology International, vol. 8, no. 4, pp. 453–471, 2014.
[25] J. H. Hu, H. F. Wang, W. P. He et al., “Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure,” Chinese Journal of Experimental and Clinical Virology, vol. 24, pp. 205–208, 2010 (Chinese).

[26] H. Gao, M. Lin, C. Pan et al., “Nucleoside analogues for acute-on-chronic liver failure associated with hepatitis B virus infection: a 24-month survival analysis,” Chinese Journal of Hepatology, vol. 23, no. 1, pp. 17–22, 2015 (Chinese).

[27] T. Chen, Y. He, X. Liu et al., “Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure,” Clinical and Experimental Medicine, vol. 12, no. 3, pp. 159–164, 2012.

[28] J. Lai, Y. Yan, L. Mai, Y.-B. Zheng, W.-Q. Gan, and W.-M. Ke, “Short-term entecavir versus lamivudine therapy for HBsAg-negative patients with acute-on-chronic hepatitis B liver failure,” Hepatobiliary and Pancreatic Diseases International, vol. 12, no. 2, pp. 154–159, 2013.

[29] W. H. Cai and C. F. Shi, “Efficacy comparison of entecavir and lamivudine in HBV-associated acute-on-chronic liver failure,” Guide of China Medicine, vol. 9, pp. 303–304, 2011 (Chinese).

[30] B. He, “Short-term efficacy comparison of lamivudine and entecavir in HBV-associated acute-on-chronic liver failure,” Hebei Medical Journal, vol. 35, pp. 661–663, 2013 (Chinese).

[31] L. Yuan, “Comparison between entecavir and lamivudine for acute on chronic liver failure caused by HBV,” China & Foreign Medical Treatment, vol. 12, pp. 107–108, 2015 (Chinese).

[32] G. Ostapowicz, R. J. Fontana, F. V. Schioedt et al., “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Annals of Internal Medicine, vol. 137, no. 12, pp. 947–954, 2002.

[33] A. Rutherford, T. Davern, J. E. Hay et al., “Influence of high body mass index on outcome in acute liver failure,” Clinical Gastroenterology and Hepatology, vol. 4, no. 12, pp. 1544–1549, 2006.

[34] C. A. Philips and S. K. Sarin, “Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16037–16052, 2014.

[35] Z. Zhao, T. Han, and Y. Gao, “Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure,” World Journal of Gastroenterology, vol. 17, pp. 3269–3272, 2009.

[36] C. M. Lange, J. Bojunga, W. P. Hofmann et al., “Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function,” Hepatology, vol. 50, no. 6, pp. 2001–2006, 2009.

[37] R.-N. Chien, C.-H. Lin, and Y.-F. Liaw, “The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B,” Journal of Hepatology, vol. 38, no. 3, pp. 322–327, 2003.

[38] A. Tsuota, Y. Arase, Y. Suzuki et al., “Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B,” Journal of Gastroenterology and Hepatology, vol. 20, no. 3, pp. 426–432, 2005.

[39] E. B. Keeffe, D. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1335–1341, 2008.